I am a Healthcare Professional outside the US and UK

I am a Healthcare Professional outside the US and UK

Click here for international medical scientific information about Oncology for Healthcare Professionals.

I am not a Healthcare Professional and I am outside the US and the UK

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information for patients, caregivers and the general public.

Country-specific medical scientific information

Country-specific medical scientific information

Country-specific medical scientific information for Healthcare Professionals.

This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com

AACR 2019

American Association for Cancer Research Congress 2019

The AACR annual meeting covers the latest scientific findings across the cancer research spectrum, including translational and clinical studies. The brightest minds from institutions across the world come together here to collaborate and share ideas.

 

Boehringer Ingelheim will present cutting-edge scientific discoveries in cancer cell and immune cell directed agents at the congress.

Publications

Come and discover more about our data during the scientific programme at AACR.

Filter by:
Presentation Type
  • All presentation types
  • Oral Presentation
  • Poster Presentation
  • e-Presentation
Tumour Type
  • All tumour types
Sunday 31st March 2019
BI 905677*, a first-in-class LRP5/6 antagonist targeting Wnt-driven proliferation and immune escape
Sunday 31st March 2019
13:00-15:00
Room A305
Presenter(s): Zinzalla et al.
Oral Presentation
Tumour Type(s): N/A
Presentation Number: DDT01-01
SMARCA4 is a selective vulnerability in SMARCA2-deficient esophageal squamous cell carcinoma cell lines
Sunday 31st March 2019
13:00-17:00
Section 15
Presenter(s): Ehrenhöfer-Wölfer et al.
Poster Presentation
Tumour Type(s): N/A
Presentation Number: 397 / 29
Selective and potent CDK8 inhibitors enhance NK cell activity and promote tumor surveillance
Sunday 31st March 2019
13:00-17:00
Section 21
Presenter(s): Hofmann et al.
Poster Presentation
Tumour Type(s): N/A
Presentation Number: 510 / 9
A novel T cell engaging bispecific antibody induces specific and efficacious lysis of small cell lung cancer cells in vitro and potent T cell re-directed anti-tumor activity in vivo
Sunday 31st March 2019
13:00-17:00
Section 23
Presenter(s): Hipp et al.
Poster Presentation
Tumour Type(s): SCLC
Presentation Number: 549 / 13
There are no publications which meet your criteria on this date
Monday 1st April 2019
BI 905711*, a novel CDH17-targeting TRAILR2 agonist, effectively triggers tumor cell apoptosis and tumor regressions selectively in CDH17-positive colorectal cancer models
Monday 1st April 2019
13:00-17:00
Section 9
Presenter(s): Garcia-Martinez et al.
Poster Presentation
Tumour Type(s): N/A
Presentation Number: 2051 / 3
Therapeutic synergy of the chimeric, oncolytic virus VSV-GP with immune modulators
Monday 1st April 2019
13:00-17:00
Section 19
Presenter(s): Müller et al.
Poster Presentation
Tumour Type(s): N/A
Presentation Number: 2267 / 26
Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells
Monday 1st April 2019
13:00-17:00
Section 35
Presenter(s): Lieb et al.
Poster Presentation
Tumour Type(s): N/A
Presentation Number: 2560 / 4
There are no publications which meet your criteria on this date
Tuesday 2nd April 2019
Structure-based PROTAC design demonstrates BAF complex ATPase vulnerabilities in cancer
Tuesday 2nd April 2019
13:00-17:00
Section 11
Presenter(s): Kögl et al.
Poster Presentation
Tumour Type(s): N/A
Presentation Number: 3849 / 24
Predicting MCL1 inhibitor sensitivity in large cell line panels using a gene expression signature
Tuesday 2nd April 2019
13:00-17:00
Section 19
Presenter(s): Wernitznig et al.
Poster Presentation
Tumour Type(s): N/A
Presentation Number: 3987 / 13
BI 907828*, a novel and potent MDM2-p53 antagonist, acts synergistically in a triple combination with anti-PD-1 and anti-LAG-3 antibodies in syngeneic mouse models of cancer
Tuesday 2nd April 2019
08:00-12:00
Section 23
Presenter(s): Rudolph et al.
Poster Presentation
Tumour Type(s): N/A
Presentation Number: 3197 / 7
BI 907828*: a novel, potent MDM2 inhibitor, inhibits GBM brain tumor stem cells in vitro and prolonged survival in orthotopic xenograft mouse models
Tuesday 2nd April 2019
08:00-12:00
Section 14
Presenter(s): Luchman et al.
Poster Presentation
Tumour Type(s): N/A
Presentation Number: 3084 / 18
Distinct immune stimulatory functions of anti-human VISTA antibodies are determined by the antibody isotype
Tuesday 2nd April 2019
08:00-12:00
Section 25
Presenter(s): Mostböck et al.
Poster Presentation
Tumour Type(s): N/A
Presentation Number: 3266 / 16
There are no publications which meet your criteria on this date
Wednesday 3rd April 2019
Epigenomic and transcriptional profiling of CRC cell lines with distinct response patterns to the BET inhibitor BI 894999*
Wednesday 3rd April 2019
08:00-12:00
Section 35
Presenter(s): Savarese et al.
Poster Presentation
Tumour Type(s): N/A
Presentation Number: 5194 / 12
There are no publications which meet your criteria on this date

Find out more about other oncology events

Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.

 

*These are investigational compounds and have not been approved. Their safety and efficacy have not been established.

 

© 2019 Boehringer Ingelheim International GmbH. All rights reserved.

 

Page last updated: February 2019